PT  - JOURNAL ARTICLE
AU  - Wendy C King
AU  - Max Rubinstein
AU  - Alex Reinhart
AU  - Robin J. Mejia
TI  - Time trends, factors associated with, and reasons for COVID-19 vaccine hesitancy in US adults: January-May 2021
AID  - 10.1101/2021.07.20.21260795
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.20.21260795
4099  - http://medrxiv.org/content/early/2021/08/26/2021.07.20.21260795.short
4100  - http://medrxiv.org/content/early/2021/08/26/2021.07.20.21260795.full
AB  - Importance COVID-19 vaccine hesitancy has become a leading barrier to increasing the US vaccination rate.Objective To evaluate time trends in COVID-19 vaccine intent during the US vaccine rollout, and identify key factors related to and self-reported reasons for COVID-19 vaccine hesitancy in May 2021.Design, Participants and Setting A COVID-19 survey was offered to US adult Facebook users in several languages yielding 5,088,772 qualifying responses from January 6 to May 31, 2021. Data was aggregated by month. Survey weights matched the sample to the age, gender, and state profile of the US population.Exposure Demographics, geographic factors, political/COVID-19 environment, health status, beliefs, and behaviors.Main Outcome Measures “If a vaccine to prevent COVID-19 were offered to you today, would you choose to get vaccinated.” Hesitant was defined as responding, probably or definitely would not choose to get vaccinated (versus probably or definitely would, or already vaccinated).Results COVID-19 vaccine hesitancy decreased by one-third from 25.4% (95%CI, 25.3, 25.5) in January to 16.6% (95%CI, 16.4, 16.7) in May, with relatively large decreases among participants with Black, Pacific Islander or Hispanic race/ethnicity and ≤high school education. Independent risk factors for vaccine hesitancy in May (N=525,644) included younger age, non-Asian race, <4 year college degree, living in a more rural county, living in a county with higher Trump vote share in the 2020 election, lack of worry about COVID-19, working outside the home, never intentionally avoiding contact with others, and no past-year flu vaccine. Differences in hesitancy by race/ethnicity varied by age (e.g., Black adults more hesitant than White adults <35 years old, but less hesitant among adults ≥45 years old), and vice versa. Almost half of vaccine hesitant respondents reported fear of side effects (49.2% [95%CI, 48.7, 49.7]) and not trusting the COVID-19 vaccine (48.4% [95%CI, 48.0, 48.9]); over one-third reported not trusting the government, not needing the vaccine, and waiting to see if safe. Reasons differed by degree of vaccine intent and by race/ethnicity.Conclusion COVID-19 vaccine hesitancy varied by demographics, geography, beliefs, and behaviors, indicating a need for a range of messaging and policy options to target high-hesitancy groups.Competing Interest StatementDrs. King, Mejia and Mr. Rubenstein have no conflict of interest to report. Dr. Reinhart received salary support from an unrestricted gift from Facebook.Funding StatementThis material is based upon work supported by Facebook (unrestricted gift) and a cooperative agreement from the Centers for Disease Control and Prevention (U01IP001121). Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of Facebook or the Centers for Disease Control and Prevention. Facebook was involved in the design and conduct of the study. The CDC provided funding only. Neither Facebook nor the Centers for Disease Control and Prevention had a role in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Carnegie Mellon University (CMU) Institutional Review Board approved the survey protocol and instrument.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSurvey microdata is available to researchers under a nondisclosure agreement protecting the confidentiality of responses. Access can be requested at https://cmu-delphi.github.io/delphi-epidata/symptom-survey/. https://cmu-delphi.github.io/delphi-epidata/symptom-survey/coding.html